40
Participants
Start Date
September 30, 2009
Primary Completion Date
December 31, 2011
Study Completion Date
September 30, 2012
DVD-R
40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
Bassett Cancer Institute, Cooperstown
Broome Oncology, Johnson City
Watson Clinic, LLP, Center for Care and Research, Lakeland
James R. Berenson, M.D., Inc., West Hollywood
Loma Linda University, Loma Linda
Santa Barbara Hematology Oncology, Santa Barbara
Comprehensive Blood and Cancer Center, Bakersfield
Hematology-Oncology Medical Group of Fresno, Inc., Fresno
Lead Sponsor
Collaborators (1)
Celgene Corporation
INDUSTRY
Oncotherapeutics
INDUSTRY